Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS.
Armstrong AJ, et al. Among authors: wang js.
Invest New Drugs. 2024 May 20. doi: 10.1007/s10637-024-01444-0. Online ahead of print.
Invest New Drugs. 2024.
PMID: 38767685
No abstract available.